{
    "clinical_study": {
        "@rank": "121034", 
        "acronym": "FAST", 
        "arm_group": [
            {
                "arm_group_label": "NVA237 followed by tiotropium", 
                "arm_group_type": "Experimental", 
                "description": "Period 1: NVA237 plus placebo to tiotropium on day 1, followed by a 7 day washout. Period 2: tiotropium plus placebo to NVA237 on day 8. Salbutamol was used as rescue medication."
            }, 
            {
                "arm_group_label": "Tiotropium followed by NVA237", 
                "arm_group_type": "Experimental", 
                "description": "Period 1: tiotropium plus placebo to NVA237 on day 1, followed by a 7 day washout. Period 2: NVA237 plus placebo to tiotropium on day 8. Salbutamol was used as rescue medication."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to further figure out differences of glycopyrronium bromide\n      compared to tiotropium in early bronchodilation measured by a comprehensive assessment of\n      lung function that includes hyperinflation and specific airway resistance in patients with\n      moderate to severe COPD."
        }, 
        "brief_title": "Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Obstructive Pulmonary Disease", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female adults aged \u226540 years\n\n          -  Patients with moderate to severe COPD defined by a post-bronchodilator Forced\n             Expiratory Volume in One Second (FEV1)/(FVC) Forced Vital Capacity ratio of <0.70 and\n             a post-bronchodilator FEV1 of  \u226470% and FEV1 \u2265 30% of predicted normal values.\n\n          -  Current or ex-smokers who have a smoking history of at least 10 pack years.\n\n        Exclusion Criteria:\n\n          -  Pregnant or nursing (lactating) women\n\n          -  Patients who have a clinically significant laboratory abnormality at run-in\n\n          -  Patients with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia or\n             bladder-neck obstruction or moderate to severe renal impairment (GFR <50\n             ml/min/1,732) or urinary retention. (BPH patients who are stable on treatment can be\n             considered).\n\n          -  Patients with any history of asthma\n\n          -  Patients with pulmonary lobectomy or lung volume reduction surgery or lung\n             transplantation\n\n          -  Patients receiving medications in the classes listed in the protocol as prohibited.\n\n        Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "152", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01922271", 
            "org_study_id": "CNVA237ADE02"
        }, 
        "intervention": [
            {
                "arm_group_label": "NVA237 followed by tiotropium", 
                "description": "NVA237 44 \u00b5g inhalation capsules once daily, delivered via single-dose dry-powder inhaler (SDDPI)", 
                "intervention_name": "NVA237", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "NVA237 followed by tiotropium", 
                "description": "Tiotropium 18 \u03bcg once daily delivered via HandiHaler\u00ae device.", 
                "intervention_name": "Tiotropium", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Tiotropium followed by NVA237", 
                "description": "Placebo to NVA237 once daily, delivered via single-dose dry-powder inhaler (SDDPI).", 
                "intervention_name": "Placebo to NVA237", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "NVA237 followed by tiotropium", 
                "description": "Placebo to tiotropium once daily delivered via HandiHaler\u00ae device", 
                "intervention_name": "Placebo to tiotropium", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "NVA237 followed by tiotropium", 
                    "Tiotropium followed by NVA237"
                ], 
                "description": "Used as resuce medication", 
                "intervention_name": "Salbutamol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Albuterol", 
                "Tiotropium", 
                "Glycopyrrolate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "COPD", 
        "lastchanged_date": "May 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "12687"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "13086"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "12203"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "12043"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany", 
                        "zip": "60596"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gelsenkirchen", 
                        "country": "Germany", 
                        "zip": "45879"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grosshansdorf", 
                        "country": "Germany", 
                        "zip": "22947"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gummersbach", 
                        "country": "Germany", 
                        "zip": "51643"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "20354"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kassel", 
                        "country": "Germany", 
                        "zip": "34121"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "zip": "04207"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "L\u00fcbeck", 
                        "country": "Germany", 
                        "zip": "23552"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "R\u00fcdersdorf", 
                        "country": "Germany", 
                        "zip": "15562"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sonneberg", 
                        "country": "Germany", 
                        "zip": "96515"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Multicenter, 2-period Single-dose Cross-over Study to Assess the Early Bronchodilation of Glycopyrronium Bromide (44 \u03bcg o.d.) Compared to Tiotropium (18 \u00b5g. o.d.) in Patients With Moderate to Severe COPD (FAST Study)", 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Standardized Forced Expiratory Volume in One Second (FEV1) AUC0-2h will be measured via spirometry. The AUC will be calculated from the FEV1 measurements obtained at timepoints between 0 min and 2h using the trapezoidal rule and will be standardized (=divided) by the measurement time (i.e. 2h).", 
            "measure": "Forced Expiratory Volume in One Second (FEV1) Area Under Curve (AUC) 0-2", 
            "safety_issue": "No", 
            "time_frame": "Day 1"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01922271"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. FEV1 will be measured by spirometry. All spirometry calibrations and evaluations will follow the recommendations of the American Thoracic Society / European Respiratory Society guidelines for acceptability.", 
                "measure": "Forced Expiratory Volume in One Second (FEV1)", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "Specific Airway Resistance (sRAW) indicates volume and resistance-dependent work of breathing needed in order to generate a reference flow rate of 1 L/s, measured by kPa*s. Whole body plethysmography (Bodybox) is used to measure SRaw.", 
                "measure": "Specific Airway Resistance (sRAW)", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "Total Lung Capacity (TLC) is the best vital capacity plus residual volume (RV). Whole body plethysmography (Bodybox) will be used to measure TLC.", 
                "measure": "Total Lung Capacity (TLC)", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "Inspiratory Capacity (IC) is the volume of air breathed in by a maximum inspiration at the end of a normal expiration. Whole body plethysmography (Bodybox) will be used to measure IC.", 
                "measure": "Inspiratory Capacity (IC)", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "Functional Residual Capacity (FRCpleth) will be measured using whole body plethysmography (Bodybox).", 
                "measure": "Functional Residual Capacity (FRCpleth)", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "Residual Volume (RV) will be measured using whole body plethysmography (Bodybox).", 
                "measure": "Residual Volume (RV)", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}